KRN7000, a novel immunomodulator, and its antitumor activities - PubMed (original) (raw)

Affiliations

• PMID: 8866665

Comparative Study

KRN7000, a novel immunomodulator, and its antitumor activities

E Kobayashi et al. Oncol Res. 1995.

Abstract

KRN7000, a compound with a novel alpha-galactosylceramide structure, showed potent tumor growth inhibitory activities in B16-bearing mice and markedly stimulated lymphocytic proliferation in allogeneic mixed leukocyte reaction, suggesting that KRN7000 is a biological response modifier. To confirm this suggestion, we examined the abilities of KRN7000 to enhance in vitro and in vivo natural killer (NK) activities, and found that KRN7000 enhanced in vitro and in vivo NK activities, and its potency on in vivo NK activity was much stronger than those of Poly I:C, which is a positive control, or the representative BRMs OK432 and Lentinan. In addition, since spleen cells intravenously treated with KRN7000 also showed potent cytotoxic activities against B16 and EL-4 cells, we evaluated the capability of KRN7000 to prolong the survival period of mice intravenously inoculated with B16 cells or mice intraperitoneally inoculated with EL-4 cells. In these models, KRN7000 (100 micrograms/kg) significantly prolonged the lifespan of mice, and its potency was stronger than that of Mitomycin C, a typical chemotherapeutic agent, in two models. These results demonstrate that KRN7000 would be a useful agent for cancer therapy.

PubMed Disclaimer

Similar articles

• Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino) -1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells.
  Yamaguchi Y, Motoki K, Ueno H, Maeda K, Kobayashi E, Inoue H, Fukushima H, Koezuka Y. Yamaguchi Y, et al. Oncol Res. 1996;8(10-11):399-407. Oncol Res. 1996. PMID: 9114432
• Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production.
  Nakagawa R, Motoki K, Nakamura H, Ueno H, Iijima R, Yamauchi A, Tsuyuki S, Inamoto T, Koezuka Y. Nakagawa R, et al. Oncol Res. 1998;10(11-12):561-8. Oncol Res. 1998. PMID: 10367937
• Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
  Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T, Yamagishi H. Fuji N, et al. Clin Cancer Res. 2000 Aug;6(8):3380-7. Clin Cancer Res. 2000. PMID: 10955826
• [Development of KRN7000, derived from agelasphin produced by Okinawan sponge].
  Natori T, Akimoto K, Motoki K, Koezuka Y, Higa T. Natori T, et al. Nihon Yakurigaku Zasshi. 1997 Oct;110 Suppl 1:63P-68P. doi: 10.1254/fpj.110.supplement_63. Nihon Yakurigaku Zasshi. 1997. PMID: 9503408 Review. Japanese.
• Therapeutic activities of PHA-L4, the mitogenic isolectin of phytohemagglutinin.
  Wimer BM. Wimer BM. Mol Biother. 1990 Jun;2(2):74-90. Mol Biother. 1990. PMID: 2194501 Review.

Cited by

• Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants.
  Subrahmanyam P, Webb TJ. Subrahmanyam P, et al. Front Biol (Beijing). 2012 Oct 1;7(5):436-444. doi: 10.1007/s11515-012-1194-2. Front Biol (Beijing). 2012. PMID: 23264781 Free PMC article.
• Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.
  Kim S, Lalani S, Parekh VV, Wu L, Van Kaer L. Kim S, et al. Expert Rev Vaccines. 2008 Dec;7(10):1519-32. doi: 10.1586/14760584.7.10.1519. Expert Rev Vaccines. 2008. PMID: 19053208 Free PMC article. Review.
• The role of NKT cells in tumor immunity.
  Terabe M, Berzofsky JA. Terabe M, et al. Adv Cancer Res. 2008;101:277-348. doi: 10.1016/S0065-230X(08)00408-9. Adv Cancer Res. 2008. PMID: 19055947 Free PMC article. Review.
• The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
  Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. Kitamura H, et al. J Exp Med. 1999 Apr 5;189(7):1121-8. doi: 10.1084/jem.189.7.1121. J Exp Med. 1999. PMID: 10190903 Free PMC article.
• Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.
  Shissler SC, Lee MS, Webb TJ. Shissler SC, et al. Front Immunol. 2017 Nov 1;8:1447. doi: 10.3389/fimmu.2017.01447. eCollection 2017. Front Immunol. 2017. PMID: 29163518 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database